27 results
8-K
EX-99.1
PRME
Prime Medicine Inc
1 Mar 24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
8:01am
our existing work, enable us to pursue additional programs, and provide access to innovation that can further advance Prime Editing. Over time, we
8-K
EX-99.1
PRME
Prime Medicine Inc
8 Jan 24
Regulation FD Disclosure
8:01am
and platform Preparation for late-stage Executed on key early hires to innovation capabilities product development of lead build out and scale … is Entering the Clinic at the Right Time: Evolving Landscape Favors Innovation in Cell and Gene Therapy Positive regulatory interactions in U.S
8-K
EX-99.2
PRME
Prime Medicine Inc
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
of investors Leveraging close relationship with founders David Liu and Andrew Anzalone to bring new innovation rapidly into Prime Medicine Aim to create
10-Q
4f46oraaqb82wdquu7yi
14 Nov 22
Quarterly report
4:46pm
424B4
mk8v6lk 2o58yfmbi9
21 Oct 22
Prospectus supplement with pricing info
4:47pm
S-1/A
oi9p1kszo x2wgi
13 Oct 22
IPO registration (amended)
10:51am
S-1
EX-10.14
d330525 gzfw4avkf
23 Sep 22
IPO registration
4:12pm
S-1
mrj vnr4jvb
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.18
rfjk572o fq
23 Sep 22
IPO registration
4:12pm
DRS/A
dd5kl7tbw9h
5 Aug 22
Draft registration statement (amended)
12:00am
DRS/A
vru v7atp
6 May 22
Draft registration statement (amended)
12:00am
DRSLTR
npabmthbfq9v5fu30jnm
8 Apr 22
Correspondence regarding draft registration statement
12:00am
DRS/A
ht0lzvi fo
8 Apr 22
Draft registration statement (amended)
12:00am
UPLOAD
qxcs5n
30 Mar 22
Letter from SEC
12:00am
DRSLTR
ux4 0bn9g6
25 Mar 22
Correspondence regarding draft registration statement
12:00am
DRS/A
zz05qo 1j7d
25 Mar 22
Draft registration statement (amended)
12:00am
UPLOAD
xnnhy
15 Mar 22
Letter from SEC
12:00am